Clinicians urge government to give access to new Alzheimer's medication
Summary
Dr. Antonette O'Connor discusses the urgent need for Irish patients to access lecanemab, a new Alzheimer's drug that slows disease progression by removing amyloid. While the treatment offers a significant step change, it is expensive and only eligible for early-stage patients, prompting clinicians to advocate for managed access programs. The conversation also covers the National Centre for Pharmacoeconomics' rejection of the drug's cost-effectiveness and the necessity for Ireland to build diagnostic infrastructure to keep pace with global advancements in dementia care.
Topics discussed
Introduction: Clinicians appeal for Alzheimer's drug access
How the new drug works: Removing amyloid to slow progression
Efficacy: 20-40% slowing and impact on quality of life
Eligibility: Only early-stage patients qualify (6% of clinic)
Cost analysis: Drug price vs. unquantified care burden
Proposed solutions: Managed access and HSE response
Infrastructure needs: Building services for new diagnostics
Future outlook: Optimism for cures and improved treatments
Listen ad-free on Castria